CFTR and cystic fibrosis: In 2023, Kondratyeva et al. [39] carried out a comprehensive study of the rare [E217G;G509D] allele and CF’s pathogenesis and conducted an assessment of the clinical outcomes, with potential implications for genetic counseling and the personalized prescription of CFTR modulators.